Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™

Patricia Kelly, PL McClean, Maximilian Ackermann, Moritz A. Konerding, Christian Holscher, CA Mitchell

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

OBJECTIVE: Cerebral microvascular impairments occurring in AD may reduce Abeta peptide clearance and impact upon circulatory ultrastructure and function. We hypothesized that microvascular pathologies occur in organs responsible for systemic Abeta peptide clearance in a model of AD and that Liraglutide (Victoza((R))) improves vessel architecture. METHODS: Seven-month-old APP/PS1 and age-matched wild-type mice received once-daily intraperitoneal injections of either Liraglutide or saline (n = 4 per group) for eight weeks. Casts of cerebral, splenic, hepatic, and renal microanatomy were analyzed using SEM. RESULTS: Casts from wild-type mice showed regularly spaced microvasculature with smooth lumenal profiles, whereas APP/PS1 mice revealed evidence of microangiopathies including cerebral microanuerysms, intracerebral microvascular leakage, extravasation from renal glomerular microvessels, and significant reductions in both splenic sinus density (p = 0.0286) and intussusceptive microvascular pillars (p = 0.0412). Quantification of hepatic vascular ultrastructure in APP/PS1 mice revealed that vessel parameters (width, length, branching points, intussusceptive pillars and microaneurysms) were not significantly different from wild-type mice. Systemic administration of Liraglutide reduced the incidence of cerebral microanuerysms and leakage, restored renal microvascular architecture and significantly increased both splenic venous sinus number (p = 0.0286) and intussusceptive pillar formation (p = 0.0129). CONCLUSION: Liraglutide restores cerebral, splenic, and renal architecture in APP/PS1 mice.
LanguageEnglish
Pages133-145
JournalMicrocirculation
Volume22
Issue number2
DOIs
Publication statusPublished - 22 Feb 2015

Fingerprint

Transgenic Mice
Kidney
Microvessels
Therapeutics
Cerebral Small Vessel Diseases
Peptides
Liver
Intraperitoneal Injections
Blood Vessels
Liraglutide
Pathology
Incidence

Keywords

  • APP/PS-1
  • mouse
  • microvasculature
  • liraglutide
  • brain
  • vascular casting

Cite this

Kelly, Patricia ; McClean, PL ; Ackermann, Maximilian ; Konerding, Moritz A. ; Holscher, Christian ; Mitchell, CA. / Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™. 2015 ; Vol. 22, No. 2. pp. 133-145.
@article{5bf996f7d40141eebb876908971045a8,
title = "Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™",
abstract = "OBJECTIVE: Cerebral microvascular impairments occurring in AD may reduce Abeta peptide clearance and impact upon circulatory ultrastructure and function. We hypothesized that microvascular pathologies occur in organs responsible for systemic Abeta peptide clearance in a model of AD and that Liraglutide (Victoza((R))) improves vessel architecture. METHODS: Seven-month-old APP/PS1 and age-matched wild-type mice received once-daily intraperitoneal injections of either Liraglutide or saline (n = 4 per group) for eight weeks. Casts of cerebral, splenic, hepatic, and renal microanatomy were analyzed using SEM. RESULTS: Casts from wild-type mice showed regularly spaced microvasculature with smooth lumenal profiles, whereas APP/PS1 mice revealed evidence of microangiopathies including cerebral microanuerysms, intracerebral microvascular leakage, extravasation from renal glomerular microvessels, and significant reductions in both splenic sinus density (p = 0.0286) and intussusceptive microvascular pillars (p = 0.0412). Quantification of hepatic vascular ultrastructure in APP/PS1 mice revealed that vessel parameters (width, length, branching points, intussusceptive pillars and microaneurysms) were not significantly different from wild-type mice. Systemic administration of Liraglutide reduced the incidence of cerebral microanuerysms and leakage, restored renal microvascular architecture and significantly increased both splenic venous sinus number (p = 0.0286) and intussusceptive pillar formation (p = 0.0129). CONCLUSION: Liraglutide restores cerebral, splenic, and renal architecture in APP/PS1 mice.",
keywords = "APP/PS-1, mouse, microvasculature, liraglutide, brain, vascular casting",
author = "Patricia Kelly and PL McClean and Maximilian Ackermann and Konerding, {Moritz A.} and Christian Holscher and CA Mitchell",
year = "2015",
month = "2",
day = "22",
doi = "10.1111/micc.12186",
language = "English",
volume = "22",
pages = "133--145",
number = "2",

}

Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™. / Kelly, Patricia; McClean, PL; Ackermann, Maximilian; Konerding, Moritz A.; Holscher, Christian; Mitchell, CA.

Vol. 22, No. 2, 22.02.2015, p. 133-145.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™

AU - Kelly, Patricia

AU - McClean, PL

AU - Ackermann, Maximilian

AU - Konerding, Moritz A.

AU - Holscher, Christian

AU - Mitchell, CA

PY - 2015/2/22

Y1 - 2015/2/22

N2 - OBJECTIVE: Cerebral microvascular impairments occurring in AD may reduce Abeta peptide clearance and impact upon circulatory ultrastructure and function. We hypothesized that microvascular pathologies occur in organs responsible for systemic Abeta peptide clearance in a model of AD and that Liraglutide (Victoza((R))) improves vessel architecture. METHODS: Seven-month-old APP/PS1 and age-matched wild-type mice received once-daily intraperitoneal injections of either Liraglutide or saline (n = 4 per group) for eight weeks. Casts of cerebral, splenic, hepatic, and renal microanatomy were analyzed using SEM. RESULTS: Casts from wild-type mice showed regularly spaced microvasculature with smooth lumenal profiles, whereas APP/PS1 mice revealed evidence of microangiopathies including cerebral microanuerysms, intracerebral microvascular leakage, extravasation from renal glomerular microvessels, and significant reductions in both splenic sinus density (p = 0.0286) and intussusceptive microvascular pillars (p = 0.0412). Quantification of hepatic vascular ultrastructure in APP/PS1 mice revealed that vessel parameters (width, length, branching points, intussusceptive pillars and microaneurysms) were not significantly different from wild-type mice. Systemic administration of Liraglutide reduced the incidence of cerebral microanuerysms and leakage, restored renal microvascular architecture and significantly increased both splenic venous sinus number (p = 0.0286) and intussusceptive pillar formation (p = 0.0129). CONCLUSION: Liraglutide restores cerebral, splenic, and renal architecture in APP/PS1 mice.

AB - OBJECTIVE: Cerebral microvascular impairments occurring in AD may reduce Abeta peptide clearance and impact upon circulatory ultrastructure and function. We hypothesized that microvascular pathologies occur in organs responsible for systemic Abeta peptide clearance in a model of AD and that Liraglutide (Victoza((R))) improves vessel architecture. METHODS: Seven-month-old APP/PS1 and age-matched wild-type mice received once-daily intraperitoneal injections of either Liraglutide or saline (n = 4 per group) for eight weeks. Casts of cerebral, splenic, hepatic, and renal microanatomy were analyzed using SEM. RESULTS: Casts from wild-type mice showed regularly spaced microvasculature with smooth lumenal profiles, whereas APP/PS1 mice revealed evidence of microangiopathies including cerebral microanuerysms, intracerebral microvascular leakage, extravasation from renal glomerular microvessels, and significant reductions in both splenic sinus density (p = 0.0286) and intussusceptive microvascular pillars (p = 0.0412). Quantification of hepatic vascular ultrastructure in APP/PS1 mice revealed that vessel parameters (width, length, branching points, intussusceptive pillars and microaneurysms) were not significantly different from wild-type mice. Systemic administration of Liraglutide reduced the incidence of cerebral microanuerysms and leakage, restored renal microvascular architecture and significantly increased both splenic venous sinus number (p = 0.0286) and intussusceptive pillar formation (p = 0.0129). CONCLUSION: Liraglutide restores cerebral, splenic, and renal architecture in APP/PS1 mice.

KW - APP/PS-1

KW - mouse

KW - microvasculature

KW - liraglutide

KW - brain

KW - vascular casting

U2 - 10.1111/micc.12186

DO - 10.1111/micc.12186

M3 - Article

VL - 22

SP - 133

EP - 145

IS - 2

ER -